Table 2

Echocardiographic Characteristics of Study Population at Baseline and 12 Months After Randomization

VariableControl Group (n = 46)Spironolactone (n = 47)p Value (Repeated-Measures ANOVA)
BaselineFollow-UpBaselineFollow-Up
LVEDV (ml)257 ± 80253 ± 89275 ± 104251 ± 105*0.06
LVESV (ml)173 ± 71168 ± 79188 ± 94171 ± 97*0.03
LVEF (%)34 ± 734 ± 933 ± 736 ± 9*0.02
LAmax (ml)99 ± 3495 ± 34102 ± 3889 ± 36*NS
E max (m/s)0.61 ± 0.200.62 ± 0.220.62 ± 0.210.59 ± 0.21NS
A max (m/s)0.72 ± 0.220.69 ± 0.190.65 ± 0.190.68 ± 0.18NS
E/A ratio1.1 ± 1.31.0 ± 0.721.2 ± 1.00.94 ± 0.640.07
DtE (ms)220 ± 69214 ± 88217 ± 93219 ± 67NS

A max = mitral A-wave velocity; ANOVA = analysis of variance; DtE = E-wave deceleration time; E max = mitral E-wave velocity; LAmax = left atrial end-systolic volume; LVEDV = left ventricular end-diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end-systolic volume.

  • * p < 0.01 vs. baseline.